Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1947 4
1948 2
1949 6
1950 4
1951 1
1955 1
1959 1
1960 2
1962 1
1965 1
1970 3
1971 4
1973 3
1974 2
1975 2
1976 2
1977 2
1978 6
1979 6
1980 6
1981 11
1982 8
1983 6
1984 5
1985 3
1986 1
1987 7
1988 6
1989 12
1990 1
1991 3
1992 3
1993 5
1994 4
1995 4
1996 8
1997 8
1998 12
1999 12
2000 8
2001 9
2002 10
2003 10
2004 6
2005 8
2006 13
2007 17
2008 11
2009 13
2010 22
2011 19
2012 18
2013 26
2014 27
2015 31
2016 18
2017 14
2018 15
2019 10
2020 18
2021 19
2022 13
2023 12
2024 11
2025 11
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

526 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Eur Urol. 2021 Feb;79(2):214-221. doi: 10.1016/j.eururo.2020.08.024. Epub 2020 Aug 28. Eur Urol. 2021. PMID: 32868138 Clinical Trial.
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulié M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7. J Clin Oncol. 2022. PMID: 35254888 Clinical Trial.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
Le cancer de vessie chez le sujet jeune, une étude de population française.
Compérat E, Larré S, Neuzillet Y, Vordos D, Soulié M, Azzouzi A, Pignot G, Durand X, Quintens H, Houede N, Jeglischi S, El Bakri A, Bigot P, Lebdai S, Rouprêt M, Pfister C. Compérat E, et al. Among authors: pfister c. Prog Urol. 2014 Nov;24(13):846. doi: 10.1016/j.purol.2014.08.140. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461667 French. No abstract available.
Sunitinib en rechallenge dans le cancer du rein métastatique-Résultats de l'étude RESUME.
Gimel P, Gross-Goupil M, Geoffrois L, Guillot A, Chevreau C, Deville J, Falkowski S, Boyle H, Baciuchka M, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Amela Y, Abadie S, Mahi N, Oudard S. Gimel P, et al. Among authors: pfister c. Prog Urol. 2014 Nov;24(13):821. doi: 10.1016/j.purol.2014.08.084. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461610 French. No abstract available.
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.
Groeneveld CS, Pfister C, Culine S, Harter V, Krucker C, Fontugne J, Dixon V, Sirab N, Bernard-Pierrot I, de Reyniès A, Radvanyi F, Allory Y; VESPER trial investigators. Groeneveld CS, et al. Among authors: pfister c. Ann Oncol. 2025 Jan;36(1):89-98. doi: 10.1016/j.annonc.2024.09.008. Epub 2024 Sep 17. Ann Oncol. 2025. PMID: 39299443 Free article. Clinical Trial.
Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique.
Murez T, Durand X, Rivoire M, Fournier G, Dariane C, Rouprêt M, Lugagne J, Bosset P, Pignot G, Hetet J, Rigaud J, Safsaf R, Pfister C, Daste A, Sèbe P, Malavaud B, Bossavy J, Houlgatte A, Avances C, Camparo P, Flechon A, Culine S, Iborra F, Mottet N, Coloby P, Soulié M. Murez T, et al. Among authors: pfister c. Prog Urol. 2014 Nov;24(13):865. doi: 10.1016/j.purol.2014.08.180. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461706 French. No abstract available.
526 results